Physician profile
Amy Nelson
NPI 1144831579
$7,587.51
in general payments reported to CMS, 2019-2025
22 companies · $3,636 in 2025
The $3,636 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,332 · 2023: $1,030 · 2024: $1,590 · 2025: $3,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,095 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,095.00 |
| Education | $161.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,491.20 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,084.12 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $805.84 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $717.17 | 2022-2025 | Invega Sustenna, Invega, Spravato |
| Teva Pharmaceuticals USA, INC. | $585.55 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $454.99 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $388.39 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $344.70 | 2025 | |
| Lundbeck LLC | $336.64 | 2022-2025 | Rexulti, Abilify Maintena |
| Indivior INC. | $334.80 | 2022-2025 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $279.98 | 2022-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $220.11 | 2022 | |
| Vanda Pharmaceuticals INC. | $208.29 | 2023-2025 | Fanapt, Hetlioz |
| Corium, LLC | $53.59 | 2022 | |
| Supernus Pharmaceuticals, INC. | $52.69 | 2024 | Qelbree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) Ltd. | $40.59 | 2025 | Erzofri Extended-Release |
| Bausch Health US, LLC | $40.06 | 2022-2023 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $38.02 | 2022 | |
| Almatica Pharma LLC | $31.65 | 2022-2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $30.77 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $24.45 | 2025 | Cobenfy |
| Tris Pharma INC | $23.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.